Amgen goes to FDA early with new leukemia drug

Amgen ($AMGN), which recently said it would cut back its R&D operations by closing a center in Seattle, is hoping to redeem its drug development rep by going to the FDA with an application for its new leukemia drug blinatumomab based on promising Phase II data, FierceBiotech reports. New immuno-oncology therapies that spur an immune system attack on cancer have become the rage. Story | More